Similar to the effect of gene silencing of survivin, the pharmacological inhibition of survivin by YM155, the most widely investigated survivin suppressant, diminished survivability of a varied panel of RCC cells comprising different histological subtypes (clear cell and papillary RCCs) and contrasting VHL status (VHL- null, VHL positive). The gene discussed is VHL; the disease is renal cell carcinoma.